120 F.4th 278
1st Cir.2024Background
- Investors, led by Sophia Zhou, filed a federal securities fraud class action against Desktop Metal, Inc. and several executives after Desktop Metal’s stock dropped in late 2021 following disclosures of internal compliance failures and product recalls.
- Desktop Metal is a public company focused on 3D printing, which acquired EnvisionTEC (specializing in medical/dental 3D printing) in early 2021.
- The litigation centers on two key products: Flexcera resin (used for dentures) and the PCA 4000 curing box. Allegations involve manufacturing Flexcera at a non-FDA-registered facility and promoting the PCA 4000 for uses not cleared by the FDA.
- After a whistleblower complaint, Desktop Metal investigated the compliance issues, disclosed them, and initiated product recalls, precipitating a significant stock price decline.
- Zhou’s complaint, based on securities fraud under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, was dismissed by the district court for failing to state a claim; Zhou appealed.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Preservation of scheme liability claim | Zhou argued that the district court erred by dismissing an unaddressed, separate Rule 10b-5 “scheme liability” claim. | Defendants contended Zhou failed to develop or preserve this claim in lower court briefing. | Not preserved; Zhou failed to develop or adequately present this claim below. |
| Adequacy of pleading securities fraud (misrepresentations/omissions) | Zhou alleged Desktop Metal made materially misleading statements and omissions regarding FDA compliance and product attributes. | Defendants asserted no materially false or misleading statements or actionable omissions were made; disclosures were adequate. | No actionable misstatements or omissions were pled; dismissal affirmed. |
| Whether generalized regulatory compliance statements are actionable | Zhou claimed that Desktop Metal’s statements created a misleading impression of full regulatory compliance. | Defendants argued statements were cautionary, qualified, or not misleading as alleged. | Court found statements non-actionable as they were general, cautionary, and not representations of full compliance. |
| Omissions about product safety/sales practices (PCA 4000/Flexcera) | Zhou asserted omissions about promoting the PCA 4000 and manufacturing Flexcera at an unregistered facility rendered statements misleading. | Defendants argued there was no duty to disclose or that statements weren't rendered misleading by omissions. | Court found omissions unrelated to scope of disclosed statements and thus not actionable. |
Key Cases Cited
- Fire & Police Pension Ass'n of Colo. v. Abiomed, Inc., 778 F.3d 228 (1st Cir.) (discussing PSLRA pleading and scienter standards for securities fraud)
- ACA Fin. Guar. Corp. v. Advest, Inc., 512 F.3d 46 (1st Cir.) (requirements for pleading material misrepresentation/omission under PSLRA)
- Hill v. Gozani, 638 F.3d 40 (1st Cir.) (analysis of pleading standards and statement-by-statement approach in securities fraud)
- Macquarie Infrastructure v. Moab Partners, L. P., 601 U.S. 257 (U.S.) (limiting actionable omissions to half-truths under Rule 10b-5)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (U.S.) (materiality standard for omissions in securities fraud)
- In re Bos. Sci. Corp. Sec. Litig., 686 F.3d 21 (1st Cir.) (actionability of omissions and half-truths in securities fraud)
- Singh v. Cigna Corp., 918 F.3d 57 (2d Cir.) (cautionary/accountability nature of compliance statements)
- Backman v. Polaroid Corp., 910 F.2d 10 (1st Cir.) (scope of disclosure and omissions in securities fraud)
- Serabian v. Amoskeag Bank Shares, Inc., 24 F.3d 357 (1st Cir.) (puffery vs. actionable false statements in securities litigation)